Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Diabetes Draft Guidance May Require Extended Trial Length, Participation

Mar 10 2008

• By Becky Jungbauer

Related Content

FDA Drug Development Guidances: Oncology, Diabetes, Obesity Are Priorities

Feb 10 2003

Avandia Should Stay On Market With Warnings, Committee Says

Aug 06 2007

Avandia Concerns Highlight Need To Change Diabetes Approval Standards

Aug 13 2007

FDA Keeping Surrogate Endpoint For Type 2 Diabetes Agent Approvals

Sep 03 2007

FDA’s Guidance Agenda Includes Risk Communication, Pain, Diabetes

Mar 26 2007

FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

Feb 19 2007

Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink

Dec 19 2005

New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ

Mar 10 2008

Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Feb 04 2008

Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Feb 18 2008

Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns

Jan 21 2008

Is Faster Better? Senators Question Surrogate Endpoints, Fast Track Status

Mar 10 2008

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window